Background: Autoantibodies targeting Ku, an abundant nuclear protein with DNA helicase activity, have been reported in patients with systemic autoimmune rheumatic diseases. Little is known about the clinical associations of anti-Ku antibodies, especially when novel diagnostic technologies are used. The objective of the present study was to analyse the prevalence of anti-Ku antibodies in different medical conditions using a novel chemiluminescent immunoassay. Patients and methods: Serum samples from adult patients with systemic lupus erythematosus (SLE, n¼305), systemic sclerosis (SSc, n¼70) and autoimmune myositis patients (AIM, n¼109) were the primary focus of the study. Results were compared with disease controls (rheumatoid arthritis, RA, n¼30; infectious diseases, n¼17) and healthy individuals (n¼167). In addition, samples submitted for routine autoantibody testing from patients referred to a rheumatology clinic (n¼1078) were studied. All samples were tested for anti-Ku antibodies by QUANTA Flash Ku chemiluminescent immunoassay (research use only, Inova Diagnostics, San Diego, USA) using full length recombinant human Ku. SLE patient samples were also tested for other autoantibodies. Clinical data of anti-Ku antibody positive patients (high titres) were obtained by retrospective chart review. Results and findings: In the disease cohorts, 30/305 (9.8%) SLE, 3/70 (4.3%) systemic sclerosis and 4/109 (3.7%) autoimmune myositis (AIM) patients were positive, respectively. The four positive AIM patients had an overlap myositis syndrome that included two patients with SLE. The three systemic sclerosis (SSc) positive samples had diagnoses of SSc/SLE overlap, diffuse cutaneous SSc, and early edematous phase SSc. In the control cohorts, 2/170 (1.2%) healthy individuals (all low titre), 0/30 (0.0%) (RA) and 0/17 (0.0%) infectious disease patients were positive. The area under the curve values were: 0.75 for SLE vs. controls, 0.68 for SSc vs. controls and 0.37 for AIM vs. controls. In the rheumatology clinic referral cohort, 12/1078 (1.1%) were positive for anti-Ku antibodies, nine showing low and three high titres. The diagnoses of the three high positive anti-Ku positive patients were: probable SLE, mixed connective tissue disease (MCTD) and ANA positive RA. Conclusion: Anti-Ku antibodies detected by chemiluminescent immunoassay are most prevalent in SLE. When found in AIM and SSc, they were associated with overlap syndrome and early SSc. Lupus (2016) 25, 889-896. Figure 1 Comparative descriptive analysis of anti-Ku antibodies measured by chemiluminescence immunoassay The QUANTA Flash Ku in different pathologies were compared. High titer of anti-Ku antibodies were restricted to SLE and AIM. Highest prevalence was found in SLE patients. Numbers on the ordinate Y-axis are relative luminescence units (RLU). SLE: systemic lupus erythematosus; AIM: autoimmune myositis; RA: Rheumatoid arthritis; ID: infectious diseases; HI: healthy individuals. Clinical and serological associations of autoantibodies to the Ku70/Ku80 heterodimer determined M Mahler et al.
Introduction
Autoantibodies targeting the Ku antigen have been reported in patients with antinuclear antibody (ANA) associated rheumatic diseases (AARDs) [1] [2] [3] such as systemic lupus erythematosus (SLE), autoimmune myositis (AIM) 4 and systemic sclerosis (SSc). 5 The Ku autoantigen is a heterodimeric protein comprising of two subunits (Ku70 and Ku80) with sequence specific binding affinity for DNA 6 and to a lesser extent for RNA. Ku is an abundant nuclear protein and is present in most eukaryotes. Ku contains ssDNA-dependent ATPase and adenosine triphosphate (ATP)dependent DNA helicase activities representing the regulatory subunit of the DNA-dependent protein kinase that phosphorylates many proteins, including SV-40 large T antigen, p53, RNA-polymerase II, RP-A, topoisomerases, hsp90, and many transcription factors. The multifunctional protein has been directly or indirectly implicated in many important cellular metabolic processes such as repair of dsDNA breaks, V(D)J recombination of immunoglobulins and T-cell receptor genes, immunoglobulin isotype switching, DNA replication, transcription regulation, regulation of heat shock-induced responses, regulation of the precise structure of telomeric termini, and a novel role in G2 and M phases of the cell cycle. 6 By indirect immunofluorescence (IIF) on HEp-2 and other tissue culture cells, human anti-Ku autoantibodies are typically associated with a fine speckled staining pattern of interphase nuclei and nucleoli. 7 Unlike antibodies to chromatin, dsDNA or DFS70, the condensed chromosome regions of mitotic cells are not stained. Several studies have investigated the somewhat complex distribution of the Ku B-cell epitopes. [8] [9] [10] [11] Although the Ku autoantibody system was described over two decades ago, tests for these autoantibodies are rarely included in diagnostic algorithms and little is known about their clinical associations, especially when newer diagnostic technologies are used.
Although no clear consensus has been reached, some studies suggested that anti-Ku antibodies are a marker for an overlap syndrome. [12] [13] [14] [15] The objective of the present study was to analyse the prevalence of anti-Ku antibodies in different conditions using a novel chemiluminescent immunoassay (CIA) on the BIO-FLASH Õ platform, a fully random access automated immunoanalyzer. 16 
Patients and methods

Sera
Based on earlier published disease associations, three disease cohorts were the primary focus of this study: sera or plasma from SLE (n¼305), SSc (n¼70) and AIM (n¼109) patients, while comparator control sera were from individuals with various other diseases and from apparently healthy individuals (for details see Figure 1 ). The specimens from SLE patients were obtained from two centres: consecutive SLE patients (n¼251) enrolled between June 2000 and August 2010 into the Dalhousie University Lupus Clinic at the Queen Elizabeth II Health Sciences Centre (Halifax, Nova Scotia, Canada) and from Wroclaw Medical University, Poland. All these patients fulfilled the American College of Rheumatology criteria for SLE. 17 SSc patient and AIM patient samples were collected at University of Calgary and University of Montreal, respectively. 4, 14 The study also included sera (n¼1078) from unselected patients referred to a rheumatology clinic who underwent ANA testing (ANA cohort). All samples were tested for anti-Ku antibodies by CIA (QUANTA Flash Õ Ku; research use only, Inova Diagnostics, San Diego, CA, USA). SLE serum samples were also tested for other autoantibodies using the respective QUANTA Lite Õ ELISAs (Inova Diagnostics). Clinical data of anti-Ku positive patients (high titres) from the ANA cohort were collected by retrospective chart review. The serological cohorts consist of patients who fulfilled classification criteria for each individual disease as previously described. 18 Collection of patient samples was carried out according to local ethics committee approval and regulations. The collection and study of clinical data and serum/plasma samples from SLE patients was approved by the Nova Scotia Health Authority Research Ethics Board, Halifax, Nova Scotia, Canada and patients provided written informed consent. Similarly, clinical data and serum samples from SSc patients were approved by the Conjoint Medical Ethics Board at the University of Calgary.
Diagnostic tests QUANTA Flash Õ Ku
The QUANTA Flash Ku (research use only) assay is a novel CIA that is currently used for research purposes only and utilizes the BIO-FLASH Õ instrument (Biokit s.a., Barcelona, Spain), fitted with a luminometer, as well as all the hardware and liquid handling accessories necessary to fully automate the assay. 19, 20 The QUANTA Flash assay for this study was developed using fulllength, purified, recombinant human heterodimeric Ku antigen (Diarect, Freiburg, Germany) coupled to paramagnetic beads. The assay measures Immunoglobulin G (IgG) to Ku and uses a 1:80 dilution of the sera. The concept of the BIO-FLASH system has been described in several studies 20 and recently summarized in a review article. 16 The cut-off for the assay was based on 99% specificity in apparently healthy individuals.
Other assays
Antibodies to dsDNA, chromatin, SSA (Ro52/tripartite motif (TRIM)21 and Ro60 mixture), SSB/ La, ribosomal P protein, C1Q, RNP and Sm were detected by the QUANTA Lite ELISAs (Inova Diagnostics) performed according to the manufacturer's instructions.
Western blot analysis
To confirm specific binding, the Ku antigen used in the CIA (Lot. 73B02, 0.8 mg/lane) was fractionated by sodium dodecyl sulphate polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. Success of transfer as verified by protein staining with Ponceau S showed two bands corresponding to the two subunits of the Ku antigen. Sera containing anti-Ku antibodies as defined using the Ku CIA were diluted 1:100 in sample diluent (kit component of QUANTA Lite ELISA, Inova Diagnostics) and incubated for 1 h at room temperature. After washing away unbound compounds, the membrane was incubated with a goat anti-human IgG conjugated with alkaline phosphatase. All membrane strips were developed at the same time using BCIP substrate.
Statistical evaluation
The data were statistically evaluated using the Analyse-it software (Analyse-it Software, Ltd, Leeds, UK). t-test was carried out to analyse the agreement between portions. Receiver-operating characteristics (ROC) analysis was used to analyse the discriminatory ability of different immunoassays. p values < 0.05 were considered significant. Cluster analysis was used to illustrate the relationship between different assays, and to display the reactivity pattern of the patients. Hierarchical clustering was performed using average linkage clustering where patient correlation was performed uncentred and the reactivities uncentred.
Results
Anti-Ku antibodies in serological cohorts
At a cut-off value of 15,000 relative light units (RLUs), 30/305 (9.8%) SLE patients, 4/109 (3.7%) AIM patients and 3/70 (4.3%) SSc patients were positive, respectively. All four positive AIM patients had a myositis overlap syndrome that included two patients with SLE and myositis. Of the three SSc positive patients, one each had SSc/overlap (highest titre), early oedematous phase SSc and diffuse cutaneous SSc. In the control cohorts, 2/167 (1.2%) healthy individuals (both low titre), 0/30 (0.0%) rheumatoid arthritis (RA) and 0/17 (0.0%) infectious disease patients were positive (see Figure  1 ). ROC analysis showed better discrimination between SLE patients and controls compared with AIM or SSc patients and controls (see Figure 2 ). The area under the curve (AUC) values were: 0.75 (95% confidence interval (CI) 0.71-0.79) for SLE vs. controls, 0.37 (95% CI 0.30-0.43) for AIM vs. controls and 0.68 (95% CI 0.60-0.77) for SSc vs. controls. When the SLE, SSc and AIM data were combined in one group and compared with the controls, the AUC was 0.65 (95% CI 0.61-0.69).
Anti-Ku antibodies in a large routine cohort
To analyse the prevalence of anti-Ku antibodies in samples from patients for whom an ANA test was ordered, we tested 1078 consecutive patient samples for anti-Ku antibodies (ANA cohort). In this rheumatology clinic referral cohort, 12/1078 (1.1%) were positive for anti-Ku antibodies, nine showing low and three high titres. The diagnoses of the three high positive anti-Ku positive patients were identified by retrospective chart review. One patient had probable SLE but did not fulfil the ACR classification criteria for SLE, 21 one patient had mixed connective tissue disease and one patient was being treated with anti-TNF for ANA positive RA.
Anti-Ku antibodies by western blot
To validate specific binding in a separate immunoassay, the Ku antigen was fractionated by SDS-PAGE and immunoreactivity analysed by western immunoblot. A total of nine anti-Ku positive samples identified by QUANTA Flash Ku were randomly selected and tested together with negative controls. All CIA positive samples reacted with at least one subunit of the Ku antigen, although the reactivity to the p70 and p80 subunits varied among the samples (see Figure 3 ). anti-dsDNA, 18/23 had anti-chromatin, 14/23 anti-RNP, 10/23 anti-Sm, 11/23 anti-SSA, 5/23 anti-SSB/La, 9/23 anti-C1Q, 2/23 anti-ribosomal P protein. Next we studied the coexistence of anti-Ku and other autoantibodies and the clinical associations using a large subset of SLE patients which had detailed clinical information available (n¼231). Anti-Ku antibodies in these sera were qualitatively associated with anti-chromatin (p<0.0001), but not with any of the other autoantibodies (Table 1) . Anti-Ku antibodies were not associated with any clinical features in our SLE cohort ( Table 1) . Serological and clinical associations were not studied in SSc and AIM patients due to the low number of anti-Ku positive samples.
Serological and clinical associations of anti-Ku autoantibodies in a cohort of 251 SLE patients
Discussion
Although first identified more than 20 years ago, 8 little is known about the clinical utility of anti-Ku autoantibodies and, accordingly, their clinical use as diagnostic or prognostic biomarkers is limited. In large part, this might be attributed to the small number of validated commercially available immunoassays for the detection of anti-Ku autoantibodies. Currently available assays that detect anti-Ku antibodies are based on line immunoassay (LIA or dot blot) technology which represents a simple approach for multiplexing autoantibody detection. 4, 22, 23 However, the LIA has limitations in terms of quantitation of autoantibody reactivity, the analytical sensitivity 3 and automation. In addition, as of March 2016, no commercial anti-Ku antibody assay has been cleared by the Food and Drug Administration in the USA. We studied the prevalence of anti-Ku antibodies in various conditions using a novel CIA wherein the highest prevalence of anti-Ku antibodies was observed in SLE patients, a finding that is consistent with previous reports. 2 In contrast, the prevalence of anti-Ku antibodies in our study was significantly lower than in two previous studies of 239 AARD and 100 AIM patients (3.7% vs. 20.5% 2 and 23.0%, 4 respectively). The discrepancy might be explained by the different assays (i.e. immunoprecipitation, ELISA, etc.) used to detect the antibodies. Only 3/23 of the line assay anti-Ku antibody positive samples were also positive by immunoprecipitation and by the CIA used in the present study. 4 Another factor influencing the prevalence of anti-Ku antibodies in AIM has been linked to the genetic background of the different populations; for example, it varied from 5% in Mediterranean patients to up to 23% in French- 
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Lupus Canadian populations. 4, 6, 22 Recently, several comprehensive studies were published that analysed autoantibodies including anti-Ku antibodies in SSc. 5, [23] [24] [25] The prevalence rate of anti-Ku antibodies was 8/57 (14.0%), 2 10/210 (4.7%), 23 10/863 (1.2%) 5 and 6/129 (4.7%), 25 which was in agreement with our data (4.3%). In SSc, anti-Ku antibodies have been reported to be associated with severe myositis and also with interstitial lung disease. 26, 27 Of note, anti-Ku antibodies were absent in ANA positive samples (n¼560) from apparently healthy individuals. 28 Besides the knowledge about the prevalence of anti-Ku antibodies in cohorts of well characterized samples, it is important to understand how frequently anti-Ku antibodies would be detected in samples submitted to an immunology service laboratory for measurement of ANA or anti-ENA antibodies and what the clinical profiles of those patients represent. In our ANA referral cohorts, anti-Ku antibodies were relatively more prevalent than in a recently published study. 29 The explanation for the difference might be the methodological difference to detect anti-Ku antibodies (CIA vs. counterimmunoelectrophoresis). Of interest, in a previous study, SSc patients were identified that had only anti-Ku antibodies as the sole autoantibody specificity.
It is noteworthy that a significant portion of studies published over the last decades were case reports [30] [31] [32] in which anti-Ku antibodies were associated with facial nerve palsy, 31 camptocormia 32 and hepatitis C virus-related hepatocellular carcinoma. 33 A recent study found different clinical associations of autoantibodies to the two Ku protein subunits. 34 Although we found a heterogeneous pattern of reactivity to the two Ku subunits (i.e. majority showing strongest reactivity to the 80 kDa subunit, see Figure 4 ), further studies are needed to confirm this potentially interesting observation.
When IIF on HEp-2 cells is used to screen for anti-Ku antibodies (by pattern identification), their prevalence is low. 26 This might be attributed to the presence of a wide spectrum of other autoantibodies in SLE patients 35 that obscure the Ku specific IIF pattern. Although IIF on HEp-2 cells is still the recommended method for ANA screening, 36 larger laboratories follow the growing demand for automation are increasingly using solid phase immunoassays in their diagnostic algorithms for ANA testing. 37, 38 Novel technologies for ANA screening show promising results for SLE and Sj-gren's syndrome, but limitations persist for SSc and AIM. 3, [39] [40] [41] In this context, SSc patients were previously reported to have anti-Ku antibodies as the only autoantibody specificity. 42 Therefore, to improve sensitivity of screening assays and multiplexed testing systems, it seems that the detection of anti-Ku is important to provide a complete autoantibody profile of a given patient being investigated for AARD.
Conclusions
Anti-Ku antibodies detected by CIA were present in 9.8% of SLE sera (depending on the cut-off), in 4.3% of SSc and in 3.7% of AIM patients. A significant portion of SSc and AIM patients had a SLE overlap syndrome. Our findings suggests that anti-Ku antibodies are primarily associated with SLE rather than with AIM. This association may have been missed in previous studies due to the use of IIF screening assays and/or the higher sensitivity of the current CIA assay. 
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